CNGCX
Price
$66.79
Change
+$0.78 (+1.18%)
Updated
Jul 31 closing price
Net Assets
51.8B
NPFCX
Price
$68.44
Change
+$0.61 (+0.90%)
Updated
Jul 31 closing price
Net Assets
170.23B
Interact to see
Advertisement

CNGCX vs NPFCX

CNGCX vs NPFCX Comparison Chart in %
View a ticker or compare two or three
VS
CNGCX vs. NPFCX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CNGCX is a Buy and NPFCX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
NPFCX has more cash in the bank: 170B vs. CNGCX (51.8B). NPFCX pays higher dividends than CNGCX: NPFCX (0.33) vs CNGCX (0.00). CNGCX was incepted earlier than NPFCX: CNGCX (24 years) vs NPFCX (25 years). CNGCX (1.52) and NPFCX (1.47) have similar cost to investors . CNGCX is a more actively managed with annual turnover of: 36.00 vs. NPFCX (23.00). CNGCX (250) and NPFCX (250) have matching initial minimum investment requirements. CNGCX annual gain was more profitable for investors over the last year : 18.55 vs. NPFCX (5.55). CNGCX return over 5 years is better than : 17.82 vs. NPFCX (7.57).
CNGCXNPFCXCNGCX / NPFCX
Total Expense Ratio1.521.47103%
Annual Report Gross Expense Ratio1.521.47103%
Fund Existence24 years25 years-
Gain YTD14.8984.473333%
Front LoadN/AN/A-
Min. Initial Investment250250100%
Min. Initial Investment IRAN/AN/A-
Net Assets51.8B170B30%
Annual Yield % from dividends0.000.33-
Returns for 1 year18.555.55334%
Returns for 3 years47.8329.60162%
Returns for 5 years17.827.57235%
Returns for 10 years99.9193.90106%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PAXLX11.280.14
+1.26%
Impax Large Cap Fund Individual Investor
AGVFX31.080.17
+0.55%
American Funds Global Insight A
ETNEX16.540.08
+0.49%
Eventide Exponential Technologies N
FSKGX20.150.09
+0.45%
Fidelity Growth Strategies K6
BMSDX17.15-0.04
-0.23%
MFS Blended Research Mid Cap Eq C